Can Any Stock Outperform Medicure?

Medicure (TSXV: MPH) in our view has a 100% chance of getting FDA approval for MC-1, which will result in them receiving their Priority Review Voucher that they will sell for US$200 million. Marley Drug alone is worth much more than MPH’s current market cap. If you look at how thousands of people are saying on X that they would love to invest in Cost Plus Drugs if it was a publicly traded company, Marley Drug is the only publicly traded equivalent. Outside of the natural resource sector there are no stocks that will outperform Medicure in 2027. Its big breakout is coming shortly. This is just like Broadvision in 2012 and Voyager in 2020.

Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. NIA’s President has purchased 87,000 shares of MPH and intends to buy more shares. This message is meant for informational and educational purposes only.